---
title: 'Senior Scientist / Scientist, In Vivo Pharmacology at NewLimit'
canonical: 'https://feeny.ai/job/senior-scientist-scientist-in-vivo-pharmacology-newlimit-south-san-francisco-t4a3w08ps5rd'
type: 'job'
last_seen: '2026-09-11'
---

# Senior Scientist / Scientist, In Vivo Pharmacology at NewLimit

- **Company:** NewLimit
- **Location:** South San Francisco, CA
- **Posted:** 2026-09-04
- **Last confirmed live:** 2026-09-11
- **Apply:** https://job-boards.greenhouse.io/newlimit/jobs/6181901004

## Job description

Company info

NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.

Description

NewLimit is seeking a talented Scientist / Senior Scientist of In Vivo Pharmacology to join our Translational Sciences team. This critical role designs and executes in vivo studies to evaluate pioneering epigenetic reprogramming therapeutics across our entire portfolio. As a subject matter expert in nonclinical and PK/PD study design, you will lead in vivo pharmacology strategies, collaborate cross-functionally with therapeutic area teams, and directly drive therapeutic candidate selection.

As a Senior Scientist/Scientist on our team, you will:

- Design, execute, and interpret in vivo pharmacology studies (PK/PD, efficacy, dose-response) across multiple disease models and therapeutic programs
- Collaborate with Epigenetic Editing, Predictive Modeling, and other therapeutic area teams to evaluate epigenetic reprogramming payloads in relevant animal models
- Develop and refine animal models of aging and age-related disease to support translational studies
- Oversee study design, protocol development, and CRO/vendor relationships for in vivo studies
- Analyze and interpret in vivo data (PK/PD, biomarkers, functional endpoints) to drive pre-clinical decision making
- Contribute to regulatory-enabling study design and documentation as programs progress toward clinical

## Requirements

- Ph.D. in pharmacology, physiology, biology or a related field or equivalent industry experience (5+ years for Scientist; 8+ years for Senior Scientist)
- Demonstrated experience designing and executing in vivo pharmacology studies (PK, PD, efficacy, dose-range finding) in rodent models
- Experience with study design, dosing regimens, and route-of-administration selection
- Experience analyzing and interpreting in vivo pharmacology data to inform program decisions
- Experience leading project workflows and providing technical mentorship to junior laboratory staff
- History of contributing to a drug development program at the pre-clinical or clinical development stage

## Nice to have

- Experience with liver biology, hepatic disease models, or hepatocyte-directed delivery
- Experience with nucleic acid or viral vector delivery in vivo
- Experience with GLP-enabling or IND-enabling study design
- Experience with single cell genomics or pooled screening approaches applied to in vivo readouts

## Benefits

NewLimit offers generous benefits to ensure our team can focus on our mission:

- Health, dental, and vision insurance
- 401(k) with company match
- Paid parental leave
- Industry-leading paid time off (PTO) — 20 days/year for all employees + holidays
- Meals and snacks on-site

Salary Range: $130,000 to $180,000. Compensation for the role will depend on a number of factors, including a candidate’s qualifications, skills, competencies, and experience. NewLimit offers a competitive benefits package, which includes a 401k, healthcare coverage, and 20 days of PTO. Learn more at: https://www.newlimit.com/careers   *This compensation and benefits information is based on Company's good faith estimate as of the date of publication and may be modified in the future.

## About NewLimit

## Company Overview
- **One-liner**: NewLimit is a biotechnology company developing epigenetic reprogramming medicines to radically extend human healthspan by reversing cellular aging.
- **Entity Type**: Private (Series B)
- **Headquarters**: South San Francisco, California, United States
- **Founded**: 2022
- **Founders**: Jacob Kimmel (Co-founder & President), Brian Armstrong (Co-founder), Blake Byers (Co-founder)

## Core Business
- **Primary industry/industries**: Biotechnology, Epigenetic Reprogramming, Longevity Therapeutics, Drug Discovery
- **Target customers**: B2B (pharmaceutical partners, clinical development), B2C (ultimately patients with age-related diseases)
- **Mission or purpose statement**: To radically extend human healthspan by creating the first medicines that reverse cellular aging at the epigenetic level.

## Products & Services
- **Discovery Engine**: An AI-powered platform that designs epigenetic payloads to make old cells look and act young. It tests thousands of designs simultaneously using genomics and retrains models iteratively on new data.
- **Therapeutics (Pipeline)**: Medicines focused on restoring youthful function in the liver, immune system, and vasculature. Initial programs target diseases resembling accelerated aging, with the goal of restoring youthful metabolism, energy levels, resilience to disease, and cognition.

## Market Standing
- **Valuation/Market Cap**: Not publicly disclosed
- **Key Metric**: Total Funding of **$215M** (across three rounds); Annual Revenue estimated at **$12.8M** [linkedin.com](https://linkedin.com/company/newlimit)
- **Notable Investors/Partners**: Kleiner Perkins (led Series B), Valor Equity Partners, Quiet Capital, S32, Duke University Management Company, Liberty Mutual Investments, Fred Ehrsam, Elad Gil, Joe Lonsdale, Eric Schmidt, Garry Tan, Brian Armstrong, Blake Byers [newlimit.com](https://www.newlimit.com/company)
- **Growth Signals**: 44 employees (+40.5% YoY), 12 active job postings (+100% YoY), LinkedIn followers grew 157.6% in the past year, and the company closed a $130M Series B in May 2025 led by Kleiner Perkins [linkedin.com](https://linkedin.com/company/newlimit).

## Competitive Advantages
- **Proprietary AI Platform**: A frontier intelligence system that designs, tests, and retrains models on epigenetic reprogramming at unprecedented scale.
- **Scientific Moats**: Deep expertise in epigenetic reprogramming (a validated but complex mechanism for reversing cellular age); a team with backgrounds from Calico, UCSF, and Stanford.
- **Founding Team & Backing**: Co-founded by Brian Armstrong (CEO of Coinbase) and Blake Byers (early investor in OpenAI, Anthropic, Neuralink), providing deep capital access and a culture of ambitious, long-term execution.

## Strategic Focus
- **Current priorities**: Advancing pipeline programs into the clinic (Head of Clinical Development role is open); scaling the Discovery Engine; building the team across computational biology, immunology, and manufacturing.
- **Direction for growth**: Transition from a discovery-stage R&D company to a clinical-stage therapeutics company; generating large revenue streams to fund the mission; expanding into new cell types and disease areas.

## Why Work Here
- **Culture**: "Not for the faint of heart" — a high-performance, mission-focused team. No pure management roles; everyone executes. Values include safety then speed, clear communication, inherent optimism, independent thinking, and top talent in every seat [newlimit.com](https://www.newlimit.com/careers).
- **Remote/Hybrid/Office**: Likely on-site/hybrid given the lab-based nature of the work (headquarters in South San Francisco).
- **Notable Perks**: Competitive salaries, comprehensive health benefits (medical, dental, vision), equity packages, 401(k) with up to 4% match, generous parental leave, 20 days PTO + 15 holidays, free EV charging [newlimit.com](https://www.newlimit.com/careers).
- **Engineering Culture**: Strong emphasis on computational biology, machine learning, and functional genomics. The team spans both wet-lab and dry-lab disciplines, with a focus on building scalable methods and iterative data-driven discovery.

## Sources
1. [NewLimit Website](https://www.newlimit.com/)
2. [NewLimit Careers Page](https://www.newlimit.com/careers)
3. [NewLimit Company Page](https://www.newlimit.com/company)
4. [NewLimit Team Page](https://www.newlimit.com/team)
5. [NewLimit LinkedIn Page](https://www.linkedin.com/company/newlimit)

## Other roles at NewLimit

- [Senior Manager, Lab Operations](https://feeny.ai/job/senior-manager-lab-operations-newlimit-south-san-francisco-2s9yfb1zrv9n) — South San Francisco, CA
- [Scientist, LNP-Lipid Chemistry](https://feeny.ai/job/scientist-lnp-lipid-chemistry-newlimit-south-san-francisco-dhqb4z5sh4rw) — South San Francisco, CA
- [Scientist, LNP-Drug Product Development](https://feeny.ai/job/scientist-lnp-drug-product-development-newlimit-south-san-francisco-nyvhkqvmdezz) — South San Francisco, CA
- [VP/Senior Director, Clinical Operations](https://feeny.ai/job/vp-senior-director-clinical-operations-newlimit-south-san-francisco-3myq4z294a7c) — South San Francisco, CA
- [Laboratory Operations Specialist](https://feeny.ai/job/laboratory-operations-specialist-newlimit-south-san-francisco-mf010pr8xwk8) — South San Francisco, CA
- [Executive Recruiter](https://feeny.ai/job/executive-recruiter-newlimit-south-san-francisco-gyv2et7crq90) — South San Francisco, CA
- [Executive Assistant](https://feeny.ai/job/executive-assistant-newlimit-south-san-francisco-jznmrqh4wrvw) — South San Francisco, CA
- [IT & Security Lead](https://feeny.ai/job/it-security-lead-newlimit-south-san-francisco-zdar0wnmwbkn) — South San Francisco, CA
- [Senior/Research Associate, Functional Genomics](https://feeny.ai/job/senior-research-associate-functional-genomics-newlimit-south-san-francisco-09h6rva4fp46) — South San Francisco, CA
- [Scientist, Drug Product Analytical](https://feeny.ai/job/scientist-drug-product-analytical-newlimit-south-san-francisco-x377jpajt45d) — South San Francisco, CA